[Uremic pruritus: an unresolved challenge].
Pruritus is a common and unpleasant symptom in the dialysis setting, affecting about half of all hemodialysis and peritoneal dialysis patients. It has a great impact on patients' quality of life and is also associated with increased mortality. The pathogenesis of uremic pruritus (UP) is clearly multifactorial and still poorly understood. At least four main hypotheses have been put forward: dermatological abnormalities, an immune-system derangement that results in a proinflammatory state, an imbalance of the endogenous opioidergic system, and a neuropathic mechanism. The neurophysiology of itch has been shown to be quite similar to that of pain, supporting the hypothesis that the two phenomena may be closely related in dialysis patients, who often also experience uremic neuropathy. Moreover, an array of other triggering factors may include uremic toxins, systemic inflammation, cutaneous xerosis, and common comorbidities such as diabetes mellitus, endocrinopathies and viral hepatitis. The first step in the treatment of UP focuses on some general strategies that include the optimization of the dialysis schedule using biocompatible membranes such as polymethyl methacrylate, and the control of the divalent ion metabolism. The second step may be local therapy with skin emollients and capsaicin creams. More specific treatments that appear promising but have not been proven to be definitively efficacious include UVB light, gabapentin and the novel k-opioid-agonist nalfurafine. Nephrologists, who still tend to neglect this disabling symptom, need to be aware that UP is associated with poorer patient outcomes and that a stepwise therapeutic approach is now available.
Struttura Complessa di Nefrologia e Dialisi, Ospedale Casa Sollievo della Sofferenza, Istituto di Ricovero e Cura a Carattere Scientifico, San Giovanni Rotondo (Foggia), Italy. f.aucella@operapadrepio.it
F
F
Aucella
A
A
Gesuete
D000279:Administration, Cutaneous; D000588:Amines / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000982:Antipruritics / Q000627:therapeutic use; D002211:Capsaicin / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004643:Emollients / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D000077206:Gabapentin; D006801:Humans; D007558:Italy / Q000453:epidemiology; D009019:Morphinans / Q000627:therapeutic use; D011379:Prognosis; D011537:Pruritus / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology / Q000532:radiotherapy; D011788:Quality of Life; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*; D012307:Risk Factors; D013141:Spiro Compounds / Q000627:therapeutic use; D016896:Treatment Outcome; D014467:Ultraviolet Therapy / Q000379:methods; D014511:Uremia / Q000150:complications* / Q000453:epidemiology / Q000628:therapy*; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D000700:Analgesics; D000982:Antipruritics; D003509:Cyclohexanecarboxylic Acids; D004643:Emollients; D009019:Morphinans; D013141:Spiro Compounds; C111212:TRK 820; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D002211:Capsaicin